IBDEI0GL ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8057,0)
 ;;=190.3^^58^605^83
 ;;^UTILITY(U,$J,358.3,8057,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8057,1,3,0)
 ;;=3^Malig Neopl Conjunctiva
 ;;^UTILITY(U,$J,358.3,8057,1,4,0)
 ;;=4^190.3
 ;;^UTILITY(U,$J,358.3,8057,2)
 ;;=Malig Neopl Conjunctiva^267274
 ;;^UTILITY(U,$J,358.3,8058,0)
 ;;=364.41^^58^605^50
 ;;^UTILITY(U,$J,358.3,8058,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8058,1,3,0)
 ;;=3^Hyphema
 ;;^UTILITY(U,$J,358.3,8058,1,4,0)
 ;;=4^364.41
 ;;^UTILITY(U,$J,358.3,8058,2)
 ;;=Hyphema^60498
 ;;^UTILITY(U,$J,358.3,8059,0)
 ;;=364.05^^58^605^51
 ;;^UTILITY(U,$J,358.3,8059,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8059,1,3,0)
 ;;=3^Hypopyon
 ;;^UTILITY(U,$J,358.3,8059,1,4,0)
 ;;=4^364.05
 ;;^UTILITY(U,$J,358.3,8059,2)
 ;;=Hypopion^60720
 ;;^UTILITY(U,$J,358.3,8060,0)
 ;;=365.02^^58^605^4
 ;;^UTILITY(U,$J,358.3,8060,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8060,1,3,0)
 ;;=3^Angle, Narrow
 ;;^UTILITY(U,$J,358.3,8060,1,4,0)
 ;;=4^365.02
 ;;^UTILITY(U,$J,358.3,8060,2)
 ;;=Angle, Narrow^268748
 ;;^UTILITY(U,$J,358.3,8061,0)
 ;;=372.63^^58^605^117
 ;;^UTILITY(U,$J,358.3,8061,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8061,1,3,0)
 ;;=3^Symblepharon
 ;;^UTILITY(U,$J,358.3,8061,1,4,0)
 ;;=4^372.63
 ;;^UTILITY(U,$J,358.3,8061,2)
 ;;=Symblepharon^265885
 ;;^UTILITY(U,$J,358.3,8062,0)
 ;;=372.75^^58^605^27
 ;;^UTILITY(U,$J,358.3,8062,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8062,1,3,0)
 ;;=3^Cysts, Conjunctival
 ;;^UTILITY(U,$J,358.3,8062,1,4,0)
 ;;=4^372.75
 ;;^UTILITY(U,$J,358.3,8062,2)
 ;;=Cysts, Conjunctival^269049
 ;;^UTILITY(U,$J,358.3,8063,0)
 ;;=364.81^^58^605^43
 ;;^UTILITY(U,$J,358.3,8063,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8063,1,3,0)
 ;;=3^Floppy Iris Syndrome
 ;;^UTILITY(U,$J,358.3,8063,1,4,0)
 ;;=4^364.81
 ;;^UTILITY(U,$J,358.3,8063,2)
 ;;=^335254
 ;;^UTILITY(U,$J,358.3,8064,0)
 ;;=006.9^^58^605^2
 ;;^UTILITY(U,$J,358.3,8064,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8064,1,3,0)
 ;;=3^Amebiasis
 ;;^UTILITY(U,$J,358.3,8064,1,4,0)
 ;;=4^006.9
 ;;^UTILITY(U,$J,358.3,8064,2)
 ;;=^5818
 ;;^UTILITY(U,$J,358.3,8065,0)
 ;;=190.8^^58^605^60
 ;;^UTILITY(U,$J,358.3,8065,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8065,1,3,0)
 ;;=3^Iris Melanoma,Contiguous Site
 ;;^UTILITY(U,$J,358.3,8065,1,4,0)
 ;;=4^190.8
 ;;^UTILITY(U,$J,358.3,8065,2)
 ;;=^267278
 ;;^UTILITY(U,$J,358.3,8066,0)
 ;;=224.1^^58^605^93
 ;;^UTILITY(U,$J,358.3,8066,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8066,1,3,0)
 ;;=3^Orbit Neoplasm,Benign
 ;;^UTILITY(U,$J,358.3,8066,1,4,0)
 ;;=4^224.1
 ;;^UTILITY(U,$J,358.3,8066,2)
 ;;=^267671
 ;;^UTILITY(U,$J,358.3,8067,0)
 ;;=360.33^^58^605^52
 ;;^UTILITY(U,$J,358.3,8067,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8067,1,3,0)
 ;;=3^Hypotony,Assoc w/ Ocular D/O
 ;;^UTILITY(U,$J,358.3,8067,1,4,0)
 ;;=4^360.33
 ;;^UTILITY(U,$J,358.3,8067,2)
 ;;=^268560
 ;;^UTILITY(U,$J,358.3,8068,0)
 ;;=224.8^^58^605^86
 ;;^UTILITY(U,$J,358.3,8068,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8068,1,3,0)
 ;;=3^Neopl Eye Bgn,Oth Iris Nevus
 ;;^UTILITY(U,$J,358.3,8068,1,4,0)
 ;;=4^224.8
 ;;^UTILITY(U,$J,358.3,8068,2)
 ;;=^267678
 ;;^UTILITY(U,$J,358.3,8069,0)
 ;;=364.01^^58^605^103
 ;;^UTILITY(U,$J,358.3,8069,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8069,1,3,0)
 ;;=3^Prim Iridocyclitis
 ;;^UTILITY(U,$J,358.3,8069,1,4,0)
 ;;=4^364.01
 ;;^UTILITY(U,$J,358.3,8069,2)
 ;;=^268704
 ;;^UTILITY(U,$J,358.3,8070,0)
 ;;=364.04^^58^605^53
 ;;^UTILITY(U,$J,358.3,8070,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8070,1,3,0)
 ;;=3^Iridociclyties 2ary,Non Infectious
 ;;^UTILITY(U,$J,358.3,8070,1,4,0)
 ;;=4^364.04
